Screening, diagnosis and risks associated with Hepatitis E virus infection.

: Hepatitis E virus (HEV) is the main cause of hepatitis worldwide. Our knowledge of this single-strand positive-sense RNA virus, discovered in the 1980s, has improved greatly in recent years. : We review the most recent information on diagnostic tools, including serological and molecular assays, the recommended diagnostic algorithm, and the clinical manifestations of HEV infections.

[Acute hepatitis E infection associated with Guillain-Barré syndrome in an immunocompetent patient].

Introduction: Hepatitis E virus (HEV) infection is now recognized to be an emerging autochthonous disease in several countries. There have been several reports of neurological manifestations associated with HEV infections. Immunocompromised patients seem to be particularly vulnerable.

Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.

Hepatitis C virus (HCV) protease inhibitor resistance-associated substitutions are selected during triple-therapy breakthrough. This multicenter quality control study evaluated the expertise of 23 French laboratories in HCV protease inhibitor resistance genotyping. A panel of 12 well-defined blinded samples comprising two wild-type HCV strains, nine transcripts from synthetic NS3 mutant samples or from clinical strains, and one HCV RNA-negative sample was provided to the participating laboratories.

Hepatitis E.

Hepatitis E virus (HEV) was discovered during the Soviet occupation of Afghanistan in the 1980s, after an outbreak of unexplained hepatitis at a military camp. A pooled faecal extract from affected soldiers was ingested by a member of the research team. He became sick, and the new virus (named HEV), was detected in his stool by electron microscopy.